Skip to content
← Catalog

ACS Nano 2026 · Spleen-Tropic LNP for in vivo CAR-T engineering · Guo/Li

"The delivery of nucleic acids via lipid nanoparticles (LNPs) to generate chimeric antigen receptor (CAR) T cells in vivo represents a promising therapeutic strategy for a broad spectrum of diseases. Nevertheless, the low efficiency of in vivo gene delivery to T cells remains a …

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_verify_wave_2_2026-05-16
evidence_grade
A
category
in_vivo_car_t_lnp_platform
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"preclinical animal model · NOT human clinical data · not intended to guide individual patient treatment choices"
journal
ACS Nano
year
2026
authors
Qiang Guo,Jinghong Li
abstract_snippet
"The delivery of nucleic acids via lipid nanoparticles (LNPs) to generate chimeric antigen receptor (CAR) T cells in vivo represents a promising therapeutic strategy for a broad spectrum of diseases. Nevertheless, the low efficiency of in vivo gene delivery to T cells remains
pmid
42130331
doi
10.1021/acsnano.6c00706
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.